TrialScientific reports2021

Feasibility of reduced-dose posttransplant cyclophosphamide and cotransplantation of peripheral blood stem cells and umbilical cord-derived mesenchymal stem cells for SAA.

Yingling Zu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.